X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8893) 8893
Book Review (1271) 1271
Publication (555) 555
Conference Proceeding (26) 26
Book Chapter (11) 11
Magazine Article (8) 8
Dissertation (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8476) 8476
index medicus (8380) 8380
taxoids - administration & dosage (5690) 5690
female (5636) 5636
oncology (5080) 5080
middle aged (4797) 4797
antineoplastic combined chemotherapy protocols - therapeutic use (4621) 4621
aged (4347) 4347
male (4143) 4143
docetaxel (4003) 4003
adult (3478) 3478
chemotherapy (3424) 3424
treatment outcome (2551) 2551
cancer (2523) 2523
breast neoplasms - drug therapy (2454) 2454
antineoplastic combined chemotherapy protocols - adverse effects (1837) 1837
taxoids - therapeutic use (1787) 1787
taxoids - adverse effects (1700) 1700
paclitaxel (1661) 1661
cisplatin - administration & dosage (1541) 1541
paclitaxel - administration & dosage (1497) 1497
breast neoplasms - pathology (1417) 1417
taxoids (1413) 1413
drug administration schedule (1404) 1404
breast cancer (1394) 1394
lung neoplasms - drug therapy (1335) 1335
neoplasm staging (1324) 1324
disease-free survival (1226) 1226
animals (1219) 1219
pharmacology & pharmacy (1193) 1193
paclitaxel - analogs & derivatives (1187) 1187
antineoplastic agents - administration & dosage (1182) 1182
aged, 80 and over (1181) 1181
fluorouracil - administration & dosage (1151) 1151
deoxycytidine - analogs & derivatives (1107) 1107
care and treatment (1100) 1100
antineoplastic combined chemotherapy protocols - administration & dosage (1096) 1096
cisplatin (1091) 1091
carcinoma, non-small-cell lung - drug therapy (1087) 1087
antineoplastic agents - therapeutic use (1082) 1082
therapy (1054) 1054
trial (1003) 1003
medicine & public health (995) 995
deoxycytidine - administration & dosage (976) 976
survival rate (940) 940
retrospective studies (866) 866
prognosis (864) 864
survival analysis (859) 859
carcinoma (827) 827
cell line, tumor (816) 816
prostatic neoplasms - drug therapy (813) 813
neoplasm metastasis (808) 808
research (806) 806
survival (803) 803
chemotherapy, adjuvant (789) 789
mice (789) 789
prostate cancer (786) 786
dose-response relationship, drug (774) 774
metastasis (759) 759
taxoids - pharmacology (756) 756
antineoplastic agents (754) 754
antineoplastic agents, phytogenic - administration & dosage (728) 728
antimitotic agents (695) 695
analysis (691) 691
hematology, oncology and palliative medicine (687) 687
neoadjuvant therapy (686) 686
combined modality therapy (662) 662
lung neoplasms - pathology (660) 660
doxorubicin (643) 643
antineoplastic agents, phytogenic - therapeutic use (629) 629
drug therapy (628) 628
cyclophosphamide - administration & dosage (618) 618
adenocarcinoma - drug therapy (614) 614
drug resistance, neoplasm (599) 599
doxorubicin - administration & dosage (596) 596
antineoplastic agents - adverse effects (592) 592
carboplatin - administration & dosage (591) 591
phase-ii trial (591) 591
combination (586) 586
paclitaxel - adverse effects (572) 572
stomach neoplasms - drug therapy (564) 564
follow-up studies (558) 558
taxoids - pharmacokinetics (555) 555
disease progression (544) 544
gemcitabine (534) 534
carcinoma, non-small-cell lung - pathology (531) 531
paclitaxel - therapeutic use (521) 521
clinical trials (517) 517
tumors (503) 503
cancer research (502) 502
prospective studies (487) 487
carcinoma, squamous cell - drug therapy (485) 485
kaplan-meier estimate (483) 483
phase-ii (481) 481
capecitabine (479) 479
antineoplastic agents - pharmacology (478) 478
neutropenia - chemically induced (475) 475
trastuzumab (468) 468
neoplasms - drug therapy (463) 463
fluorouracil (459) 459
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8009) 8009
Japanese (518) 518
Chinese (119) 119
French (87) 87
German (66) 66
Russian (35) 35
Italian (22) 22
Spanish (16) 16
Hungarian (15) 15
Lithuanian (4) 4
Portuguese (3) 3
Czech (2) 2
Dutch (2) 2
Finnish (2) 2
Korean (2) 2
Croatian (1) 1
Danish (1) 1
Norwegian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer | Index Medicus
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 4/2008, Volume 100, Issue 8, pp. 542 - 551
Background Among breast cancer patients, nonresponse to initial neoadjuvant chemotherapy is associated with unfavorable outcome. We compared the response of... 
THERAPY | GEPARDUO | ONCOLOGY | PROGNOSIS | CARCINOMA | CHEMOTHERAPY | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Alkylating - administration & dosage | Vinblastine - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Breast Neoplasms - chemistry | Carcinoma, Ductal, Breast - drug therapy | Fluorouracil - administration & dosage | Vinblastine - analogs & derivatives | Mastectomy, Segmental | Adult | Female | Breast Neoplasms - diagnostic imaging | Chemotherapy, Adjuvant | Doxorubicin - administration & dosage | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Biomarkers, Tumor - analysis | Deoxycytidine - administration & dosage | Ultrasonography, Mammary | Treatment Outcome | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Aged | Carcinoma, Lobular - drug therapy | Patient Compliance | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Germany | Chemotherapy | Breast cancer | Drug therapy | Comparative analysis | Health aspects | Cancer | Side effects | Toxicity | Clinical outcomes | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 812 - 822
Summary Background Previous trials from our group suggested an overall survival benefit with five cycles of adjuvant full-dose epirubicin plus ifosfamide in... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CRITERIA | THERAPY | RECIST | CLINICAL-TRIAL | HIGH-GRADE | ONCOLOGY | DOSE ADJUVANT CHEMOTHERAPY | EXTREMITIES | TUMOR RESPONSE ASSESSMENT | IFOSFAMIDE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Trabectedin | Sarcoma - therapy | Young Adult | Neurilemmoma - therapy | Dioxoles - administration & dosage | Back | Adult | Neutropenia - chemically induced | Child | Extremities | Soft Tissue Neoplasms - therapy | Dacarbazine - administration & dosage | Thoracic Wall | Sarcoma, Synovial - therapy | Deoxycytidine - administration & dosage | Risk Factors | Docetaxel | Anemia - chemically induced | Etoposide - administration & dosage | Tetrahydroisoquinolines - administration & dosage | Thrombocytopenia - chemically induced | Abdominal Wall | Sarcoma - pathology | Leiomyosarcoma - therapy | Disease-Free Survival | Taxoids - administration & dosage | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Neoadjuvant Therapy - methods | Adolescent | Soft Tissue Neoplasms - pathology | Aged | Deoxycytidine - analogs & derivatives | Liposarcoma, Myxoid - therapy | Care and treatment | Anthracyclines | Sarcoma | Adjuvant treatment | Clinical trials | Product development | Standards | Cancer | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 16, pp. 4534 - 4539
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2013, Volume 31, Issue 7, pp. 860 - 867
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 387, Issue 10024, pp. 1163 - 1177
Summary Background Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled... 
Internal Medicine | ANDROGEN-DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | PREDNISONE | DESIGN | MITOXANTRONE | CABAZITAXEL | CLINICAL-TRIALS | OPEN-LABEL | CHEMOTHERAPY | ENZALUTAMIDE | ESTRAMUSTINE | Survival analysis | Medical prognosis | Clinical trials | Hormone replacement therapy | Metastasis | Prostate cancer | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 03/2012, Volume 158, Issue 3, pp. 470 - 478
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 05/2017, Volume 523, Issue 1, pp. 300 - 309
Metastasis impedes the successful chemotherapy for breast cancer. In this study, an Akt inhibitor (quercetin, Qu) was co-delivered with a chemotherapeutic... 
Metastasis docetaxel | Breast cancer | Akt/MMP-9 pathway | Hyaluronic acid | Quercetin | MMP-9 EXPRESSION | TARGETED DRUG-DELIVERY | POLYMERIC MICELLES | CELLULAR UPTAKE | COLON-CANCER | TUMOR XENOGRAFTS | IN-VIVO | COMBINATION CHEMOTHERAPY | PHARMACOLOGY & PHARMACY | ANTICANCER DRUGS | PI3K/AKT SIGNALING PATHWAY | Alct/MMP-9 pathway | Polyethylenes - administration & dosage | Antioxidants - chemistry | Nanoparticles - chemistry | Apoptosis - drug effects | Matrix Metalloproteinase Inhibitors - administration & dosage | Matrix Metalloproteinase Inhibitors - pharmacokinetics | Antineoplastic Agents - administration & dosage | Breast Neoplasms | Polyethylenes - pharmacokinetics | Lactic Acid - pharmacokinetics | Matrix Metalloproteinase 9 - metabolism | Quercetin - pharmacokinetics | Imines - chemistry | Quercetin - administration & dosage | Female | Antineoplastic Agents - pharmacokinetics | Proto-Oncogene Proteins c-akt - metabolism | Lactic Acid - administration & dosage | Polyethylenes - chemistry | Wound Healing - drug effects | Imines - administration & dosage | Polyglycolic Acid - administration & dosage | Taxoids - chemistry | Cell Survival - drug effects | Hyaluronic Acid - administration & dosage | Lactic Acid - chemistry | Quercetin - chemistry | Hyaluronic Acid - chemistry | Matrix Metalloproteinase Inhibitors - chemistry | Antineoplastic Agents - chemistry | Hyaluronic Acid - pharmacokinetics | Imines - pharmacokinetics | Taxoids - pharmacokinetics | Cell Movement - drug effects | Taxoids - administration & dosage | Animals | Polyglycolic Acid - pharmacokinetics | Polyglycolic Acid - chemistry | Antioxidants - administration & dosage | Cell Line, Tumor | Mice, Inbred BALB C | Nanoparticles - administration & dosage | Antioxidants - pharmacokinetics | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Nanoparticles | Chemotherapy | Cancer cells | Metastasis | Cancer | Index Medicus
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 1/2008, Volume 100, Issue 2, pp. 121 - 133
Background Docetaxel is more effective than doxorubicin for patients with advanced breast cancer. The Breast International Group 02-98 randomized trial tested... 
CANCER PATIENTS | 1ST-LINE TREATMENT | PHASE-II TRIAL | THERAPY | EPIRUBICIN | ONCOLOGY | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | METHOTREXATE | COMBINATION CHEMOTHERAPY | FLUOROURACIL | CMF | Immunohistochemistry | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Adenocarcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Mastectomy - methods | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Tamoxifen - administration & dosage | Receptors, Progesterone - analysis | Antineoplastic Agents, Phytogenic - administration & dosage | Breast Neoplasms - chemistry | Fluorouracil - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Odds Ratio | Adenocarcinoma - chemistry | Doxorubicin - administration & dosage | Drug Administration Schedule | Estrogen Receptor Modulators - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Lymphatic Metastasis | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Methotrexate - administration & dosage | Aged | Adenocarcinoma - surgery | Breast cancer | Dosage and administration | Drug therapy | Comparative analysis | Doxorubicin | Docetaxel | Clinical trials | Comparative studies | Chemotherapy | Index Medicus | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article